Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3906545 | 0.98 | POLB (0.52) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL27447923 | 0.97 | POLB (0.51) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| SCHEMBL10350813 | 0.86 | ALDH1A1 (0.47) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| SCHEMBL6038596 | 0.86 | POLB (0.52) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| SCHEMBL3919900 | 0.84 | VCAM1 (0.60) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| SCHEMBL8960247 | 0.84 | POLB (0.53) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL27294434 | 0.84 | ALDH1A1 (0.44) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| SCHEMBL6038599 | 0.83 | POLB (0.52) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| SCHEMBL540736 | 0.83 | POLB (0.52) | POLBMCOLN3ALDH1A1LMNAMAPK1 | |
| SCHEMBL19071890 | 0.82 | MAPT (0.46) | POLBLMNAMEN1KMT2AVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426781-B1 | MICRORNAS AND METHODS OF THEIR USE | US HEALTH (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230295631-A1 | MICRORNAS AND METHODS OF THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226013-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | Carmel-Haifa University Economic Corp Ltd. (IL) | 2023-07-20 | — | — | US | disclosed |
| EP-3834882-B1 | TREATING CANCER USING ELECTROMAGNETIC FIELDS IN COMBINATION WITH OTHER TREATMENT REGIMENS | NOVOCURE GMBH (CH) | 2023-07-19 | — | — | EP | disclosed |
| US-11690810-B2 | Combination treatment of bacterial infection | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11655469-B2 | MicroRNAs and methods of their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-23 | — | — | US | disclosed |
| EP-3834882-A1 | TREATING CANCER USING ELECTROMAGNETIC FIELDS IN COMBINATION WITH OTHER TREATMENT REGIMENS | Novocure GmbH (CH) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021111443-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CARMEL - HAIFA UNIVERSITY ECONOMIC CORP LTD. (IL) | 2021-06-10 | — | — | WO | disclosed |
| EP-3386596-B1 | TOPICAL SKIN CARE COMPOSITIONS COMPRISING MYRSINE AFRICANA EXTRACTS | UNIV PRETORIA (ZA) | 2021-05-12 | — | — | EP | disclosed |
| CN-112739207-A | Liquid for preserving mammalian cells comprising an acarbose or stachyose | 株式会社大塚制药工场 | 2021-04-30 | — | — | CN | disclosed |
| EP-0935415-A4 | METHODS FOR DELIVERING COMPOUNDS INTO A CELL | IMARX PHARMACEUTICAL CORP (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1218494-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G2 CELL CYCLE ARREST AND SENSITIZING CELLS TO DNA DAMAGING AGENTS | Canbas Co., Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-20010031740-A1 | Methods for delivering compounds into a cell | IMARX PHARMACEUTICAL CORPORATION | 2001-10-18 | — | — | US | disclosed |
| WO-2001021771-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G2 CELL CYCLE ARREST AND SENSITIZING CELLS TO DNA DAMAGING AGENTS | CANBAS CO., LTD. (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000003245-A1 | PEPTIDE LIGANDS FOR THE HUMAN FIBROBLAST GROWTH FACTOR (FGF) RECEPTOR | CHUGAI PHARMACEUTICAL COMPANY LIMITED (JP) | 2000-01-20 | — | — | WO | disclosed |
| WO-1999047151-A1 | PEPTIDE LIGANDS FOR THE ERYTHROPOIETIN RECEPTOR | CHUGAI PHARMACEUTICAL CO., LTD. (JP) | 1999-09-23 | — | — | WO | disclosed |
| EP-0935415-A1 | METHODS FOR DELIVERING COMPOUNDS INTO A CELL | IMARX PHARMACEUTICAL CORP. (US) | 1999-08-18 | — | — | EP | disclosed |
| WO-1998020037-A1 | METHOD FOR TREATING CERTAIN PEDIATRIC ACUTE LEUKEMIAS | EMORY UNIVERSITY (US) | 1998-05-14 | — | — | WO | disclosed |
| US-5698193-A | ADMINISTERING IN OVO AN IMMUNE LYMPHOKINE OBTAINED FROM A DONOR ANIMAL THAT HAS BEEN IMMUNIZED WITH AN IMMUNOGEN | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF AGRICULTURE (US) | 1997-12-16 | — | — | US | disclosed |
| WO-1997040679-A1 | METHODS FOR DELIVERING COMPOUNDS INTO A CELL | IMARX PHARMACEUTICAL CORP. (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690810-B2 | Combination treatment of bacterial infection | PGC, NRDC, PYCARD | MEN1 4072/4885POLB 1406/4885MCOLN3 3774/4885 |
| US-20010031740-A1 | Methods for delivering compounds into a cell | ABCB4, NPC1L1, IAPP | MEN1 1692/4885POLB 1755/4885MCOLN3 2655/4885 |
| US-20230226013-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CYCS, SOX18, RPS8 | MEN1 3283/4885POLB 978/4885MCOLN3 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.